# A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects

> **NCT04949490** · PHASE2 · COMPLETED · sponsor: **BioNTech SE** · enrollment: 137 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** BNT162b2s01
- **BIOLOGICAL:** BNT162b2

## Key facts

- **NCT ID:** NCT04949490
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-26
- **Primary completion:** 2022-04-14
- **Final completion:** 2022-09-16
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04949490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04949490, "A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04949490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*